|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
ɳ���Ȱ� |
|
Ƥ������ |
|
���� |
| ��������������� | |
|
�º� |
|
�ｨ�� |
| PubMed | |
|
Article by CHEN Hao |
|
Article by SUN Jian-fang |
ɳ���Ȱ�����Ƥ�����Ľ�չ
�º�, �ｨ��
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
ɳ���Ȱ�������һ�ִ�ͳ����ֹʹҩ��,�仹�ڿ��ס����ߵ��ڼ��������ȷ����нϺõ�����,�ٴ�����������ҩ�������һЩ����������Ч���ó������Ʋ�����Ӧ�ϴ�ļ��������,ɳ���Ȱ���Ƥ���������������Ž�Ϊ������Ӧ��ǰ����������ɳ���Ȱ���Ƥ���������е�Ӧ�ú����û��Ƶȷ���Ľ�չ��
Treatment of Some Skin Diseases with Thalidomide
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
Thalidomide is a traditional sedative-analgesic. Recently, it has been discovered to be a good anti-inflammatory, immunoloregulatory and antitumor agent. It can be used to treat some refractory diseases and has less adverse effect in the treatment of some diseases when compared to other routine approaches. Therefore, there is a good prospect for it in the treatment of skin diseases. This article summarizes the application and mechanism of action of thalidomide in the treatment of some skin diseases.
[2] Turk BE,Jiang H,Liu JO.Binding of thalidomide to alphal -acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.Proc Natl Acad Sci U S A,1996,93:7552-7556.
[3] Bohle AS,KalthoffH.Molecular mechanisms of tumor metastasis and angiogenesis.Langenbecks Arch Surg,1999,384:133-140.
[4] Yasui K,Kobayashi N,Yamazaki T,et al.Thalidomide as an immunotherapeutic agent:the effects on neutrophil-mediated inflammation.Curr Pharm Des,2005,11:395-401.
[5] Du GJ,Lin HH,Xu QT,et al.Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis.Vascul Pharmacol,2005,43:112-119.
[6] Tadesse A,Shannon EJ.Effects of thalidomide on intracellular Mycobacterium leprae in normal and activated macrophages.Clin Diagn Lab Immunol,2005,12:130-134.
[7] Villahermosa LG,Fajardo TT Jr,Abalos RM,et al.A randomized,double-blind,double-dummy,controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum.Am J Trop Med Hyg,2005,72:518-526.
[8] Cuadrado MJ,Karim Y,Sanna G,et al.Thalidomide for the treatment of resistant cutaneous lupus:efficacy and safety of different therapeutic regimens.Am J Med,2005,118:246-250.
[9] Gambini D,Carrera C,Passoni E,et al.Thalidomide treatment for hypertrophic cutaneous lupus erythematosus.J Dermatolog Treat,2004,15:365-371.
[10] Lu KQ,Brenneman S,Bums R Jr,et al.Thalidomide inhibits UVB-induced mouse keratinocyte apoptosis by both TNF-alpha-dependent and TNF-alpha-independent pathways.Photodermatol Photoimmunol Photomed,2003,19:272-280.
[11] Cummins DL,Gaspari AA.Photoprotection by thalidomide in patients with chronic cutaneous and systemic lupus erythematosus:discordant effects on minimal erythema dose and sunburn cell formation.Br J Dermatol,2004,151:458-464.
[12] Nasca MR,O' Toole EA,Palicharla P,et al.Thalidomide increases human keratinocyte migration and proliferation.J Invest Dermatol,1999,113:720-724.
[13] Hamuryudan V,Mat C,Saip S,et al.Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome.A randomized,double-blind,placebo-controlled trial.Ann Intern Med,1998,128:443-450.
[14] Kari JA,Shah V,Dillon MJ.Behcet's disease in UK children:clinical features and treatment including thalidomide.Rheumatology (Oxford),2001,40:933-938.
[15] Sayarlioglu M,Kotan MC,Topcu N,et al.Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease.Ann Pharmacother,2004,38:808-811.
[16] Revuz J,Guillaume JC,Janier M,et al.Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.Arch Dermatol,1990,126:923-927.
[17] Bonnetblanc JM,Royer C,Bedane C.Thalidomide and recurrent aphthous stomatitis:a follow-up study.Dermatology,1996,193:321-323.
[18] Eisen D,Lynch DP.Selecting topical and systemic agents for recurrent aphthous stomatitis.Cutis,2001,68:201-206.
[19] Paterson DL,Georghiou PR,Allworth AM,et al.Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.Clin Infect Dis,1995,20:250-254.
[20] Radomsky CL,Levine N.Thalidomide.Dermatol Clin,2001,19:87-103.
[21] Settles B,Stevenson A,Wilson K,et al.Down-regulation of cell adhesion molecules LFA-1 and ICAM-1 after in vitro treatment with the anti-TNF-alpha agent thalidomide.Cell Mol' Biol(Noisy-le-grand),2001,47:1105-1114.
[22] Browne PV,Weisdorf DJ,DeFor T,et al.Response to thalidomide therapy in refractory chronic graft-versus-host disease.Bone Marrow Transplantation.2000,26:865-869.
[23] Kulkarni S,Powles R,Sirohi B,et al.Thalidomide after allogeneic haematopoietic stem cell transplantation:activity in chronic but not in acute graft-versus-host disease.Bone Marrow Transplant,2003,32:165-170.
[24] Chao NJ,Parker PM,Niland JC,et al.Paradoxical effect of thalidomide prophylaxis on chronic graft-vs.-host disease.Biol Blood Marrow Transplant,1996,2:86-92.
[25] Little RF,Wyvill KM,Pluda JM,et al.Activity of thalidomide in AIDS-related Kaposi's sarcoma.J Clin Oncol,2000,18:2593-2602.
[26] Fife K,Howard MR,Gracie F,et al.Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre.Int J STD AIDS,1998,9:751-755.
[27] Vacca A,Scavelli C,Montefusco V,et al.Thalidomide downregulares angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.J Clin Oncol,2005,23:5334-5346.